CAS: Early access to Medicines Scheme for Remdesivir in the treatment of COVID-19

1 June 2020

A positive Scientific Opinion for remdesivir in the treatment of COVID-19 has been published by the Medicines and Healthcare Products Regulatory products Agency (MHRA). It advises on the conditions where the technology will be used and commissioned by the NHS.

Hospitals who have registered an interest in participating in COVID-19 Early Access to Medicines Scheme (EAMS) should use the country specific EAMS application process to apply for access to remdesivir for eligible patients.

This alert provides information on medicine supply, access criteria, data collection and implementation.

Further information can be found here.

ENDS